Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 13, 2015

View Archived Issues

Gene Techno Science grants exclusive rights to Mochida for codevelopment of biosimilars

Development of a chimeric IL-1R antagonist that is activated in vivo during inflammation

Discovery and preclinical development of a MCH-R1 antagonist candidate for weight control

Clovis Oncology enters into trial collaboration with Genentech

Development of a second-generation utrophin modulator for the treatment of DMD

G1 initiates two phase Ib/IIa trials of G1T28 for SCLC

Novartis studies MCS-110 in phase II trial for triple negative breast cancer

CNFT gene therapy protects cone photoreceptors in a mouse model of retinitis pigmentosa

Sorrento Therapeutics announces new acquisitions and agreements

Neuropore announces phase I trials of NPT200-11 for the treatment of Parkinson's disease

FDA accepts NDA filing for SD-809 for Huntington disease

Phase II study of venetoclax meets primary endpoint

PsychoGenics licenses new alpha-synuclein transgenic mouse model from UCSD

Codexis signs agreement for use of CodeEvolver technology

Ceftobiprole receives FDA QIDP designation for lung and skin infections

Poseida and Janssen agree to use Centyrins in the development of CAR therapies

Cytos Biotechnology licenses CYT-003 and VLP platform to Checkmate Pharmaceuticals

CMC Biologics to develop and manufacture MAbs for PATH Malaria Vaccine Initiative

NIDA grant supports Southern Research's work on opioid drugs

Midatech and Ophthotech sign agreement to explore sustained delivery formulations

Merck & Co. discloses beta-lactamase inhibitors

Roche patents muscarinic M1 PAMs

Jiangsu Carefree Pharmaceutical introduces JAK inhibitors

AlphaBeta divulges Abeta neurotoxicity inhibitors

Daiichi Sankyo discloses compounds for hyperphosphatemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...